FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963527493> ?p ?o ?g. }

• W1963527493 endingPage "5066" @default.
• W1963527493 startingPage "5058" @default.
• W1963527493 abstract "Abstract Purpose: We conducted a first-in-human phase I study to determine the dose-limiting toxicity (DLT), evaluate the pharmacokinetic profile, and document any antitumor activity of NK012, a novel SN-38–incorporating micellar nanoparticle. Experimental Design: Patients with solid tumors refractory to standard therapy, or for which no standard therapy is available, were enrolled. NK012 was administered as a 30-minute infusion every 3 weeks. The starting dose was 2 mg/m2 as SN-38 equivalent, and an accelerated titration schedule was used. Pharmacokinetic analysis was conducted in cycles 1 and 2. Results: Twenty-four patients were enrolled in the study. No UGT1A1*28 homozygous patients were enrolled. Predominant toxicity was neutropenia. Nonhematologic toxicity, especially diarrhea, was mostly grade 1 or 2 during study treatments. Two of nine patients had DLT during cycle 1 at the 28 mg/m2 dose level. DLTs were mostly neutropenia or a related event. Polymer-bound SN-38 (NK012) and SN-38 released from NK012 were slowly eliminated from the plasma, with a terminal-phase half-life of approximately 140 and 210 hours, respectively. Systemic exposure to both polymer-bound SN-38 and SN-38 increased in proportion to the dose. A refractory esophageal cancer patient and a lung carcinoid tumor patient had an objective response and continued the study treatment for 5 and 12 months, respectively. Conclusions: NK012 was well tolerated and showed antitumor activity including partial responses and several occurrences of prolonged stable disease across a variety of advanced refractory cancers. Phase II studies are ongoing. Clin Cancer Res; 16(20); 5058–66. ©2010 AACR." @default.
• W1963527493 created "2016-06-24" @default.
• W1963527493 creator A5001115937 @default.
• W1963527493 creator A5010371346 @default.
• W1963527493 creator A5017255080 @default.
• W1963527493 creator A5024904484 @default.
• W1963527493 creator A5028273614 @default.
• W1963527493 creator A5046248239 @default.
• W1963527493 creator A5056915467 @default.
• W1963527493 creator A5079864042 @default.
• W1963527493 creator A5080426166 @default.
• W1963527493 creator A5082832235 @default.
• W1963527493 creator A5090452045 @default.
• W1963527493 date "2010-10-13" @default.
• W1963527493 modified "2023-10-16" @default.
• W1963527493 title "Phase I Study of NK012, a Novel SN-38–Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors" @default.
• W1963527493 cites W1774923611 @default.
• W1963527493 cites W1960327677 @default.
• W1963527493 cites W1977482169 @default.
• W1963527493 cites W1977553393 @default.
• W1963527493 cites W2000941201 @default.
• W1963527493 cites W2010113256 @default.
• W1963527493 cites W2023804262 @default.
• W1963527493 cites W2024086872 @default.
• W1963527493 cites W2056347214 @default.
• W1963527493 cites W2059570216 @default.
• W1963527493 cites W2073683299 @default.
• W1963527493 cites W2079123814 @default.
• W1963527493 cites W2087830545 @default.
• W1963527493 cites W2102258001 @default.
• W1963527493 cites W2128447158 @default.
• W1963527493 cites W2131748114 @default.
• W1963527493 cites W2141086589 @default.
• W1963527493 cites W2151806628 @default.
• W1963527493 cites W2153017356 @default.
• W1963527493 cites W2153957030 @default.
• W1963527493 cites W2246769930 @default.
• W1963527493 cites W2253383659 @default.
• W1963527493 cites W2308212596 @default.
• W1963527493 cites W2314927739 @default.
• W1963527493 doi "https://doi.org/10.1158/1078-0432.ccr-10-0387" @default.
• W1963527493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20943763" @default.
• W1963527493 hasPublicationYear "2010" @default.
• W1963527493 type Work @default.
• W1963527493 sameAs 1963527493 @default.
• W1963527493 citedByCount "131" @default.
• W1963527493 countsByYear W19635274932012 @default.
• W1963527493 countsByYear W19635274932013 @default.
• W1963527493 countsByYear W19635274932014 @default.
• W1963527493 countsByYear W19635274932015 @default.
• W1963527493 countsByYear W19635274932016 @default.
• W1963527493 countsByYear W19635274932017 @default.
• W1963527493 countsByYear W19635274932018 @default.
• W1963527493 countsByYear W19635274932019 @default.
• W1963527493 countsByYear W19635274932020 @default.
• W1963527493 countsByYear W19635274932021 @default.
• W1963527493 countsByYear W19635274932022 @default.
• W1963527493 countsByYear W19635274932023 @default.
• W1963527493 crossrefType "journal-article" @default.
• W1963527493 hasAuthorship W1963527493A5001115937 @default.
• W1963527493 hasAuthorship W1963527493A5010371346 @default.
• W1963527493 hasAuthorship W1963527493A5017255080 @default.
• W1963527493 hasAuthorship W1963527493A5024904484 @default.
• W1963527493 hasAuthorship W1963527493A5028273614 @default.
• W1963527493 hasAuthorship W1963527493A5046248239 @default.
• W1963527493 hasAuthorship W1963527493A5056915467 @default.
• W1963527493 hasAuthorship W1963527493A5079864042 @default.
• W1963527493 hasAuthorship W1963527493A5080426166 @default.
• W1963527493 hasAuthorship W1963527493A5082832235 @default.
• W1963527493 hasAuthorship W1963527493A5090452045 @default.
• W1963527493 hasConcept C112705442 @default.
• W1963527493 hasConcept C121608353 @default.
• W1963527493 hasConcept C126322002 @default.
• W1963527493 hasConcept C142424586 @default.
• W1963527493 hasConcept C159985019 @default.
• W1963527493 hasConcept C192562407 @default.
• W1963527493 hasConcept C2776694085 @default.
• W1963527493 hasConcept C2777063308 @default.
• W1963527493 hasConcept C2778850193 @default.
• W1963527493 hasConcept C2780259306 @default.
• W1963527493 hasConcept C2780508388 @default.
• W1963527493 hasConcept C29730261 @default.
• W1963527493 hasConcept C526805850 @default.
• W1963527493 hasConcept C71924100 @default.
• W1963527493 hasConcept C90924648 @default.
• W1963527493 hasConceptScore W1963527493C112705442 @default.
• W1963527493 hasConceptScore W1963527493C121608353 @default.
• W1963527493 hasConceptScore W1963527493C126322002 @default.
• W1963527493 hasConceptScore W1963527493C142424586 @default.
• W1963527493 hasConceptScore W1963527493C159985019 @default.
• W1963527493 hasConceptScore W1963527493C192562407 @default.
• W1963527493 hasConceptScore W1963527493C2776694085 @default.
• W1963527493 hasConceptScore W1963527493C2777063308 @default.
• W1963527493 hasConceptScore W1963527493C2778850193 @default.
• W1963527493 hasConceptScore W1963527493C2780259306 @default.
• W1963527493 hasConceptScore W1963527493C2780508388 @default.
• W1963527493 hasConceptScore W1963527493C29730261 @default.
• W1963527493 hasConceptScore W1963527493C526805850 @default.

• next